P27Kip1 as a prognostic factor in breast cancer: A systematic review and meta-analysis

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 4, 2010, Pages 944-953

  Guan, Xiaoxiang ^a,b   Wang, Yucai ^b,c   Xie, Ruilian ^a   Chen, Longbang ^a   Bai, Jianling ^d   Lu, Jia ^b   Kuo, Macus Tien ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Meta analysis; P27; Prognosis

Indexed keywords

CDKN1B PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADJUVANT THERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; META ANALYSIS; METABOLISM; REVIEW; RISK FACTOR;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOADJUVANT THERAPY; RISK FACTORS;

EID: 77953952433     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00730.x     Document Type: Article

References (48)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001, 2:133-40.
2. Lee JS, Kim HS, Jung JJ. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. Appl Immunohistochem Mol Morphol 2002, 10:289-95.
3. Olewniczak S, Chosia M, Kwas A. Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol 2002, 53:183-8.
4. Catzavelos C, Bhattacharya N, Ung YC. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997, 3:227-30.
5. Tan P, Cady B, Wanner M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997, 57:1259-63.
6. Porter PL, Malone KE, Heagerty PJ. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997, 3:222-5.
7. Gillett CE, Smith P, Peters G. Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol 1999, 187:200-6.
8. Volpi A, De Paola F, Nanni O. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 2000, 63:181-92.
9. Reed W, Florems VA, Holm R. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch 1999, 435:116-24.
10. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-34.
11. Chu JS, Huang CS, Chang KJ. p27 expression as a prognostic factor of breast cancer in Taiwan. Cancer Lett 1999, 141:123-30.
12. Leong AC, Hanby AM, Potts HW. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer 2000, 89:26-31.
13. Chappuis PO, Kapusta L, Begin LR. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 2000, 18:4045-52.
14. Leivonen M, Nordling S, Lundin J. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001, 67:15-22.
15. Spataro VJ, Litman H, Viale G. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 2003, 97:1591-600.
16. Barnes A, Pinder SE, Bell JA. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol 2003, 201:451-9.
17. Esteva FJ, Sahin AA, Rassidakis GZ. Jun activation domain binding protein 1 expression is associated with low p27(Kip1) levels in node-negative breast cancer. Clin Cancer Res 2003, 9:5652-9.
18. McCallum M, Baker C, Gillespie K. A prognostic index for operable, node-negative breast cancer. Br J Cancer 2004, 90:1933-41.
19. Chappuis PO, Donato E, Goffin JR. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 2005, 16:735-42.
20. Traub F, Mengel M, Luck HJ. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 2006, 99:185-91.
21. Kamel A, Mokhtar N, Elshakankiry N. The prognostic impact of some cell cycle regulatory proteins in Egyptian breast cancer patients. J Egypt Natl Canc Inst 2006, 18:93-102.
22. Gonzalez-Angulo AM, Guarneri V, Gong Y. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer 2006, 7:326-30.
23. Millar EK, Tran K, Marr P. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence. Pathol Int 2007, 57:183-9.
24. Tsuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 1999, 70:230-4.
25. Han S, Park K, Kim HY. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat 1999, 55:161-7.
26. Wu J, Shen ZZ, Lu JS. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 1999, 79:1572-8.
27. Barbareschi M, van Tinteren H, Mauri FA. p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000, 89:236-41.
28. Lau R, Grimson R, Sansome C. Low levels of cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int J Oncol 2001, 18:17-23.
29. Nohara T, Ryo T, Iwamoto S. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology 2001, 60:94-100.
30. Liang J, Zubovitz J, Petrocelli T. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002, 8:1153-60.
31. Pohl G, Rudas M, Dietze O. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 2003, 21:3594-600.
32. Han S, Park K, Bae BN. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 2003, 83:241-7.
33. Foulkes WD, Brunet JS, Stefansson IM. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004, 64:830-5.
34. Schöndorf T, Göhring UJ, Becker M. High apoptotic index correlates to p21 and p27 expression indicating a favorable outcome of primary breast cancer patients, but lacking prognostic significance in multivariate analysis. Pathobiology 2004, 71:217-22.
35. Slotky M, Shapira M, Ben-Izhak O. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res 2005, 7:R737-44.
36. Porter PL, Barlow WE, Yeh IT. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006, 98:1723-31.
37. Kourea HP, Koutras AK, Zolota V. Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast. Anticancer Res 2006, 26:1657-68.
38. Tsutsui S, Inoue H, Yasuda K. Inactivation of PTEN is associated with a low p27Kip1 protein expression in breast carcinoma. Cancer 2005, 104:2048-53.
39. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997, 47:28-51.
40. Goldhirsch A, Glick JH, Gelber RD. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998, 90:1601-8.
41. Uzzan B, Nicolas P, Cucherat M. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004, 64:2941-55.
42. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001, 6:375-92.
43. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008, 8:253-67.
44. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993, 341:418-22.
45. Alkarain A, Jordan R, Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 2004, 9:67-80.
46. Ishida N, Hara T, Kamura T. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002, 277:14355-8.
47. Kossatz U, Vervoorts J, Nickeleit I. C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J 2006, 25:5159-70.
48. Guan X, Chen L, Wang J. Protein profiling: a possible molecular mechanism to mislocalization and down-expression of p27(Kip1) in tumor cells. Med Hypotheses 2007, 69:580-3.